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Abstract
Background: Health related quality of life (HRQOL) is an important outcome after treatment for
upper gastrointestinal carcinoma. This study aimed to compare HRQOL in patients with advanced
gastric cancer (GC) receiving either a standard or an experimental treatment.
Methods:  Seventy-one patients have been treated in Cancer Institute (Tehran, Iran) with
docetaxel, cisplatin, 5 FU (TCF) or epirubicin, cisplatin, 5-FU (ECF) and were followed from Jan
2002 to Jan 2005. End points were response rate, HRQOL and survival. HRQOL was assessed
using the EORCT QLQ-C30 at baseline and after the third cycle of chemotherapy.
Results: The baseline HRQOL scores were comparable between two groups. After treatment
improvement was seen in a number of items and domains except for cognitive functioning, and
diarrhoea. Pain decreased and physical functioning improved in both groups. However, only the
TCF group showed statistically and clinically meaningful improvement in global QOL (P = 0.001).
Surgical and pathologic response was better with TCF but there was no difference in survival rate
between two groups.
Conclusion: Docetaxel based treatment (TCF) showed better palliation and improvement of
global QOL as compared with epirubicin based treatment (ECF). However, it seems that regardless
of treatment offered, effective chemotherapy was the most important factor affecting QOL in these
patients.
Background
When assessing the value of a particular anticancer treat-
ment it is important to consider the impact it may have
not only on length of survival but also on health related
quality of life (HRQOL). In medical care of patients with
gastric cancer, the 5-year survival is a crucial outcome.
However, in the last few years there has been an increasing
awareness about quality of survival. HRQOL especially is
important for patients suffering from advanced gastric
cancer, whose life expectancy may be short [1]. Despite
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the fact that numerous comparative therapeutic studies
have been completed, there are relatively few reports of
comparisons of the HRQOL effects of these differing ther-
apies. Given that most patients with advanced gastric can-
cer are not cured and many regimens have similar efficacy,
differences in HRQOL may help to determine which regi-
men is preferred [2]. As it has been suggested using quality
of life assessment in clinical trials of patients with gastric
cancer will help to define the role of potentially curative
surgery, palliative treatments and adjuvant therapy [3]. A
recent study demonstrated that quality of life might
improve in patients with advanced gastric cancer, treated
with second-line chemotherapy [4].
This article reports the results of HRQOL assessments
obtained at baseline and after 3 cycles of chemotherapy in
Iranian patients with advanced gastric adenocarcinoma
enrolled in a randomized clinical trial of docetaxel, cispl-
atin, 5-FU versus epirubicin, cisplatin, 5-FU.
Methods
Design
Patients with histological confirmed gastric adenocarci-
noma were entered into this randomized trial. Patients
with primary or recurrent gastric adenocarcinoma (stage
III or IV) were randomly assigned to receive three to six
cycles of either ECF (epirubicin 60 mg/m2, cisplatin 60
mg/m2 and 5-FU 750 mg/m2/day as 5 days continuous
infusion) or TCF (docetaxel 60 mg/m2, cisplatin 60 mg/
m2 and 5-FU 750 mg/m2 in the same dose and schedule of
ECF) every 3 weeks. There were no industry funding, fees
or salary for this protocol.
The primary objective of the study was to determine
whether substitution of docetaxel for epirubicin in combi-
nation with cisplatin and 5-FU would improve response
rate of advanced gastric cancer. Secondary endpoints were
QOL, overall survival, and progression-free survival [5].
The Cancer Research Center review board approved the
study and all patients signed the written informed consent
dictated by the ethics committee of Tehran University of
Medical Sciences.
Quality of life assessment
QOL was assessed using the Iranian version of the Euro-
pean Organization for Research and Treatment of Cancer
Quality of Life Questionnaire, EORTC QLQ-C30 [6]. It is
one of the best-known cancer-specific questionnaires for
measuring QOL in cancer patients [7]. The questionnaire
is consisting of 30 items assessing five functional domains
(physical, role, emotional cognitive, and social), symp-
tom scales (fatigue, nausea and pain) and six single items
(dyspnoea, sleep disturbances, appetite loss, constipation,
diarrhoea, and financial impact of the disease and treat-
ment), and a single global QOL scale. Quality of life was
assessed before the first cycle of chemotherapy, and
within one month after the third cycle of chemotherapy.
Statistical analysis
For comparing patients' characteristics in two groups t-test
or chi-square were used. The QLQ-C30 responses were
scored and analyzed according to the scoring manual pro-
vided by the EORTC Study Group on Quality of Life [8].
First, the mean baseline scores for each treatment groups
were calculated. Then, after treatment, the mean change
score from baseline was calculated for all patients and
compared between the two treatment groups. Two-related
sample t-test (paired samples t-test) was used for statisti-
cal comparison. Survival analysis was performed using the
Kaplan-Meier test.
Results
Between January 2002 and January 2005, 86 patients were
randomized into the two study groups. Objective
response rate (more than 50% decreases in tumor size)
was seen in 37% and 42% of ECF and TCF group respec-
tively. Although surgery results were better in the TCF
group (P = 0.01), we did not find statistically significant
differences in clinical response to chemotherapy (Table
1).
For HRQOL evaluation, only 71 patients were included in
the comparative analysis because 15 patients did not com-
plete the QOL measurements at the beginning of the
study. Table 1 shows demographic and clinical character-
istics of the study sample, as well as the 71 participants in
the QOL assessment by the treatment arms. They were
quite similar. Most patients underwent a laparotomy
before the study and had measurable residual or meta-
static disease. The most frequent sites of disease at the
time of random assignment were peritoneum, liver and
paraaortic lymph nodes in both groups. Compliance with
QOL questionnaire completion was excellent. Less than
4% of items had missing data.
The baseline quality of life scores for each study arms are
shown in Table 2. At baseline and before chemotherapy
patients in both groups showed impairment of global
quality of life and most of functioning scales except for
cognitive functioning. The baseline QOL scores were com-
parable between two groups, with the exception of emo-
tional functioning and a better global QOL in the ECF
group.
Table 3 lists the mean score changes from baseline to post
treatment by the two study arms. Generally both groups
showed improvements compared with their baseline sta-
tus in a number of domains and items except for cognitive
functioning, diarrhoea and financial aspect of disease and
treatment that showed deterioration. Although in bothBMC Cancer 2006, 6:274 http://www.biomedcentral.com/1471-2407/6/274
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groups physical functioning improved and pain decreased
but only in the TCF group statistically and clinically signif-
icant improvement was observed for global QOL (P =
0.001), social (P = 0.03) and emotional functioning (P =
0.004), pain (P = 0.03) and sleep difficulties (P = 0.02).
To examine whether the observed differences were signif-
icant, comparisons were made and the results are shown
in Table 4. As indicated there were no significant differ-
ences between two groups after treatment except for social
functioning (P = 0.03) and nausea and vomiting (P =
0.01) in the TCF group.
Patients with proven tumor regression most frequently
had an improvement of HRQOL domains (by example
the follow-up global quality of life scores for responding
and not responding patients to chemotherapy is shown in
Figure 1. However, the median survival time for both
groups was 12 months with a 95% confidence interval of
8 to 14 and 7 to 17 months for the ECF and TCF groups
respectively.
Discussion
This trial was undertaken primarily to determine if TCF
offered superior response rate compared with a standard
ECF treatment. QOL measures were assessed to provide
patient-reported symptoms, both disease and treatment
related, as well as providing a general assessment of global
well-being and functional status of patients treated with
these chemotherapy regimens. The study demonstrated a
better response with the TCF group (although not signifi-
cant) and very similar survival between two regimens [5].
Based on our data the TCF regimen was associated with a
meaningful improvement in health related QOL.
Although overall about 40% of the patients had major
response to chemotherapy [5], the study findings suggest
that improvement of HRQOL was due to palliative effect
Table 1: The characteristics of patients in each treatment arms
ECF group1 TCF group2 P4
All (n = 42) No. (%) QOL3 (n = 35) No. (%) All (n = 44) No. (%) QOL3 (n = 36) No. (%)
Age 0.23
Mean (SD) 57. 2 (9.83) 58.1 (10.48) 55.4 (14.04) 54.2 (16.18)
Gender 0.20
Male 34 (81) 28 (80) 31 (70) 24 (67)
Female 8 (19) 7 (20) 13 (30) 12 (33)
Tumor size 0.48
T2 8 (19) 8 (23) 5 (11) 5 (14)
T3 15 (36) 12 (34) 15 (34) 11 (31)
T4 19 (45) 15 (43) 24 (55) 20 (55)
Lymph node 0.39
L1 20 (48) 18 (51) 14 (32) 14 (39)
L2 17 (40) 13 (37) 20 (45) 14 (39)
Not involvement 5 (12) 4 (12) 10 (23) 8 (22)
Differentiation 0.30
Well differentiated 7 (17) 7 (20) 5 (11) 4 (11)
Others 35 (83) 28 (80) 39 (89) 32 (89)
Tumor of cardia 0.56
Yes 19 (45) 14 (40) 15 (34) 12 (33)
Others 23 (55) 21 (60) 29 (66) 24 (67)
Metastatic site 0.92
Liver 7 (17) 7 (20) 9 (20) 7 (20)
Peritoneum 13 (31) 10 (29) 14 (32) 9 (25)
Para aortic 5 (12) 4 (11) 3 (7) 3 (8)
Multiple sites 17 (40) 14 (40) 18 (41) 17 (47)
Primary disease 0.93
Yes 30 (71) 24 (69) 33 (75) 25 (69)
No (recurrent) 12 (29) 11 (31) 11 (25) 11 (31)
Response to chemotherapy 0.69
Responding (complete and partial) 17 (40) 13 (37) 18 (41) 15 (42)
Not responding (stable or progressive disease) 25 (60) 22 (63) 26 (59) 21 (58)
1 Epirubicin, cisplatin and 5-FU
2 Docetaxel, cisplatin and 5-FU
3 Those who completed the quality of life questionnaire
4 P values derived from t-test or chi-square analyses for comparison between two groups of patients who completed the quality of life questionnaireBMC Cancer 2006, 6:274 http://www.biomedcentral.com/1471-2407/6/274
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Table 3: Quality of life mean score changes before and after 3 cycles of chemotherapy (follow-up scores minus baseline scores) for each 
study arms
ECF group TCF group
Functioning scores1 Mean (SD) score changes P3 Mean (SD) score changes P3
Physical functioning 4.1 (13.6) 0.08 2.3 (14.8) 0.36
Role functioning 0.57 (14.3) 0.81 2.7 (18.9) 0.38
Emotional functioning -0.06 (8.3) 0.96 8.0 (15.4) 0.004
Cognitive functioning -2.5 (13.4) 0.27 -6.1 (17.0) 0.04
Social functioning -2.3 (14.6) 0.36 5.2 (14.1) 0.03
Global quality of life 2.4 (14.5) 0.34 9.7 (16.8) 0.001
Symptom scores2
Fatigue -0.99 (14.8) 0.69 -4.6 (14.1) 0.05
Nausea and vomiting -3.5 (19.6) 0.29 -1.4 (29.9) 0.78
Pain -6.3 (14.2) 0.01 -5.7 (15.1) 0.03
Dyspnoea -2.6 (14.9) 0.31 -0.92 (20.3) 0.78
Sleep difficulties -5.8 (23.5) 0.15 -11.3 (27.5) 0.02
Appetite loss -4.6 (19.8) 0.17 -5.4 (29.3) 0.27
Constipation -1.1 (29.4) 0.83 0.92 (36.9) 0.88
Diarrhoea 9.8 (19.0) 0.004 0.32 (27.6) 0.94
Financial difficulties 9.1 (23.6) 0.03 11.6 (19.3) 0.001
1 For functioning scores positive values show improvements and negative values indicate deteriorations.
2 For symptom scores negative values show improvements and positive values indicate deteriorations.
3 P values derived from the paired t-tests.
SD = Standard deviation
Table 2: Quality of life baseline scores as measured by the EORTC QLQ-C30 for each study arms
ECF group TCF group P
Mean (SD) Mean (SD)
Functioning scores*
Physical functioning 65.3 (13.4) 66.1 (11.1) 0.79
Role functioning 68.5 (15.5) 68.0 (18.4) 0.89
Emotional functioning 64.0 (12.1) 56.6 (14.7) 0.02
Cognitive functioning 85.7 (10.8) 84.2 (14.3) 0.61
Social functioning 68.1 (13.6) 68.5 (13.1) 0.89
Global quality of life 55.2 (17.4) 45.1 (14.4) 0.01
Symptom scores**
Fatigue 43.5 (14.8) 49.6 (17.3) 0.11
Nausea and vomiting 22.8 (19.8) 33.8 (23.7) 0.04
Pain 40.0 (16.7) 47.1 (21.2) 0.12
Dyspnoea 7.62 (16.3) 12.0 (21.3) 0.33
Sleep difficulties 31.4 (25.5) 40.7 (21.2) 0.09
Appetite loss 39.0 (22.1) 46.3 (24.3) 0.19
Constipation 14.3 (21.8) 14.8 (26.9) 0.93
Diarrhoea 3.81 (10.7) 9.25 (18.8) 0.14
Financial difficulties 52.4 (20.2) 44.4 (21.1) 0.11
* Higher scores show better functioning and global quality of life.
** Higher scores indicate greater symptoms.BMC Cancer 2006, 6:274 http://www.biomedcentral.com/1471-2407/6/274
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of chemotherapy. The lack of apparent impact of toxicity
on global functioning of responding patients is clinically
useful data that may assist both the patient and the physi-
cian in the discussion about the anticipated effects of the
proposed chemotherapy treatment.
The EORTC QLQ-C30 was sensitive to detect HRQOL
issues that were important to patients within our specific
treatment groups. To identify aspects of HRQOL in which
the patients clearly had gained meaningful improvement,
a significant change of 5 points and p value less than 0.03
was considered to be important [9]. Accordingly one
might argue that patients in the TCF group experienced a
better QOL after their treatments. For example the TCF
group shoed 9.7 points change in their baseline global
quality of life while the same figure for the ECF group was
2.4 points.
As in any HRQOL analysis, the data need to be interpreted
with caution bearing in mind the study limitations. This
study represents QOL information for 71 patients (80% of
patients who took part in the study), although their base-
line characteristics were comparable with the entire
patients. In addition, the baseline QOL scores and symp-
toms in some patients may have been due to the effect of
surgery (laparotomy) rather than gastric cancer itself.
Thus, improvement in QOL and symptoms may have
occurred even in the absence of chemotherapy. However,
one should consider that HRQOL improvement was con-
fined only to the responders and were not seen in patients
Table 4: Comparison of quality of life scores between two groups after treatment
ECF group TCF group
Functioning scores1 Mean (SD) score Mean (SD) score P3
Physical functioning 69.4 (14.9) 68.3 (19.1) 0.81
Role functioning 69.1 (16.7) 70.8 (21.2) 0.71
Emotional functioning 63.9 (12.5) 64.6 (13.5) 0.82
Cognitive functioning 83. 2 (11.4) 78.1 (13.1) 0.08
Social functioning 65. 8(15.6) 73.7 (15.5) 0.03
Global quality of life 57.6 (15.1) 54.8 (16.3) 0.46
Symptom scores2
Fatigue 42.5 (12.7) 44.9 (16.7) 0.48
Nausea and vomiting 19.3 (16.7) 32.4 (26.1) 0.01
Pain 32.8 (17.1) 41.4 (22.6) 0.08
Dyspnoea 7.6 (16.3) 11.1 (21.1) 0.13
Sleep difficulties 25.5 (21.4) 29.4 (22.2) 0.45
Appetite loss 34.4 (24.9) 40.8 (27.7) 0.31
Constipation 13.2 (21.2) 15.7 (25.8) 0.65
Diarrhoea 13.6 (19.9) 9.5 (17.0) 0.35
Financial difficulties 61.4 (25.7) 56.0 (24.8) 0.37
1 Higher scores show better functioning and global quality of life.
2 Higher scores indicate greater symptoms.
3 P values derived from independent samples t-tests.
SD = Standard deviation
Follow-up global quality of life scores in responding and not  responding patients for each treatment group (Higher values  show better global quality of life) Figure 1
Follow-up global quality of life scores in responding and not 
responding patients for each treatment group (Higher values 
show better global quality of life): ECF: Mean score (SD); 
Responding 63.5 (14.2), Not responding 54.2 (14.9). TCF: 
Mean score (SD); Responding 63.3 (16.6), Not responding 
48.8 (13.5).
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who experienced progression of the disease. There is evi-
dence that the type of surgery does not significantly influ-
ence the quality of life in patients undergoing curative
surgery for gastric cancer [10].
Unfortunately at the time of current project the Iranian
version of the FACT-G (a well known general cancer spe-
cific quality of life questionnaire) or EORTC QLQ-STO22,
a site-specific measure of quality of life in patients with
gastric cancer were not available to use in this study.
Therefore it is important that in the future studies at least
to supplement the QLQ-C30 with the QLQ-STO22 in
measuring quality of life in patients with gastric cancer
undergoing surgery, surgery and chemo-radiotherapy,
palliative chemotherapy, palliative surgery and best sup-
portive care [11]. As suggested QOL in patients with gas-
tric cancer deserves more systematic studies, especially as
one of the outcome measures in randomized clinical trials
[1].
Conclusion
In conclusion, QOL measures provide helpful informa-
tion of patient-reported symptoms that is essential for full
evaluation of new treatments for patients with gastric can-
cer. The study findings indicated that the group treated
with TCF enjoyed more improvement with regard to glo-
bal QOL as compared with the group that treated with
ECF. However, it seems that regardless of treatment
offered, effective chemotherapy was the most important
factor affecting QOL in these patients.
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